Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695034 | 0.95 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL20157582 | 0.90 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL29073 | 0.84 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL4298088 | 0.83 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL7075683 | 0.80 | KMT2A (0.57) | L3MBTL1ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL6485416 | 0.80 | HTT (0.53) | L3MBTL1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL3012179 | 0.80 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL5779054 | 0.80 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1HTTTP53MAPT | |
| SCHEMBL527397 | 0.79 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1HTTMAPTMEN1 | |
| SCHEMBL2971365 | 0.77 | MEN1 (0.42) | HTTTP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | L3MBTL1 3440/4885ALDH1A1 3226/4885HTT 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.